SCHEMBL13600199

SCHEMBL13600199

CNC(=O)c1cc(-c2cnc3c(c2)c(Cc2cccc(Cl)c2)nn3C)ccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
MERTK Q12866 2/20 0.40
AXL P30530 1/20 0.40
CYP3A4 P08684 2/20 0.38
MAP4K1 Q92918 2/20 0.38
SCN9A Q15858 1/20 0.38
NR3C1 P04150 1/20 0.38
GSK3B P49841 1/20 0.38
SRC P12931 1/20 0.37
VEGFA P15692 1/20 0.37
FLT1 P17948 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
EGLN3 Q9H6Z9 1/20 0.37
JAK1 P23458 4/20 0.36
JAK2 O60674 3/20 0.36
TYK2 P29597 3/20 0.36
JAK3 P52333 2/20 0.36
ABL1 P00519 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12344669 0.86 MAPK1 (0.39) MAPK1MERTKAXLCYP3A4MAP4K1
SCHEMBL13600201 0.73 ALDH1A1 (0.39) MAPK1CYP3A4GSK3B
SCHEMBL3489336 0.73 MAP4K1 (0.43) MERTKAXLCYP3A4MAP4K1SRC
SCHEMBL13600200 0.73 SRC (0.42) SRCADRA1AHRH1ADRA1BPRMT5
SCHEMBL3488624 0.73 MAP4K1 (0.56) CYP3A4MAP4K1ABL1
SCHEMBL3488620 0.65 MAP4K1 (0.45) MAPK1CYP3A4MAP4K1JAK1JAK2
SCHEMBL14887078 0.65 SMN1; SMN2 (0.56) SCN9AGSK3B
SCHEMBL140037 0.64 FADS1 (0.59) ABL1
SCHEMBL3460143 0.63 PIK3C3 (0.56) MERTKAXLJAK1JAK2TYK2
SCHEMBL9280625 0.62 IKBKE (0.46) ABL1METPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 MAPK1 319/4885MERTK 399/4885AXL 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.